NCT06440213View on ClinicalTrials.gov

A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals

NACompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

December 22, 2024

Study Completion Date

February 1, 2025

Conditions
Pre DiabetesOverweight
Interventions
DIETARY_SUPPLEMENT

PeptiControl™ (Low - Dose 435 mg/day)

Plant protein hydrolysate

DIETARY_SUPPLEMENT

PeptiControl™ (Mid - Dose 870 mg/day)

Plant protein hydrolysate

DIETARY_SUPPLEMENT

PeptiControl™ (High - Dose 2610 mg/day)

Plant protein hydrolysate

DIETARY_SUPPLEMENT

Placebo Microcrystalline Cellulose

Placebo MCC micro-crystalline cellulose

Trial Locations (4)

411033

Ashwin Medical Foundation, Pune

411062

Imperial Multispeciality Hospital, Pune

422005

Chopda Medicare & Research Centre, Nashik

422010

Vakretund Hospital, Nashik

All Listed Sponsors
lead

Nuritas Ltd

INDUSTRY

NCT06440213 - A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals | Biotech Hunter | Biotech Hunter